Search Results "#GLP1"

Blogs

arrow_forward View More Results
Sitagliptin Phosphate Market: How Is the First-in-Class DPP-4 Inhibitor Navigating the GLP-1 Revolution?
Posted by Surbhi on July 14 2026 at 08:23 PM   public
Sitagliptin phosphate — the first-in-class dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck (Januvia/Janumet), enhancing endogenous incretin hormone activity to improve glycemic contro...
GLP-1 Receptor Agonist Market Growth Outlook: USD 7.9 Billion by 2036, India - CAGR 8.4%, China - CAGR 7.1%, Germany - CAGR 6.6%
Posted by Alexa morgan on September 28 2026 at 01:48 PM   public
The global GLP-1 receptor agonist market growing from USD 3 billion in 2026 to USD 7.9 billion by 2036, expanding at a CAGR of 11.7% during the forecast period. The market is gaining momentum as ...
GLP-1 Analogues Market Set to Surpass US$ 211.8 Billion by 2035 as Diabetes and Obesity Cases Accelerate Globally
Posted by Sandeep gade on June 25 2026 at 11:22 PM   public
The global GLP-1 analogues market is experiencing unprecedented growth, driven by the rising prevalence of type 2 diabetes, obesity, and associated cardiovascular disorders. Valued at US$ 51.6 bi...
GLP-1 Analogues Market to Surpass US$ 211.8 Billion by 2035, Driven by Rising Diabetes and Obesity Burden Worldwide
Posted by Sandeep gade on June 16 2026 at 09:37 PM   public
The global GLP-1 analogues market was valued at US$ 51.6 Billion in 2024 and is projected to reach US$ 211.8 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 13.7% during the...
Global GLP-1 Analogues Market to Surpass US$ 211.8 Billion by 2035 Amid Rising Diabetes and Obesity Cases
Posted by Sandeep gade on June 09 2026 at 03:35 AM   public
The global GLP-1 analogues market is experiencing unprecedented growth, driven by the increasing prevalence of type 2 diabetes and obesity, expanding therapeutic applications, and continuous inno...
arrow_forward